{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:06:31Z","timestamp":1781618791914,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abbott"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study systematically reviewed economic evaluations of FreeStyle Libre systems (FSL) for glucose monitoring among people living with type 1 (T1DM) or type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches were conducted on 27 February 2024 using the MEDLINE, Embase, and Cochrane databases. Study selection was conducted by two reviewers who independently reviewed titles, abstracts, and full article texts. Study quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 18 cost-effectiveness studies were included; 17 were based on data for the original FSL device, with only one using FSL2 data. There were no major issues with study quality. The ten studies comparing FSL with self-monitoring of blood glucose (SMBG) reported FSL to be cost effective in populations with T1DM (seven studies) or T2DM (six studies). Eight studies reported other sensor-based systems to be cost effective versus FSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Existing evidence suggests FSL systems are cost effective versus SMBG among people living with T1DM or T2DM on intensive insulin. Additional studies are needed to compare FSL systems with other sensor-based systems, considering the range of available evidence, the appropriateness of the compared devices, and the selection of modelling assumptions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-025-00673-1","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:42:43Z","timestamp":1763545363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic analyses of freestyle libre systems for people living with diabetes: a systematic literature review"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-6823","authenticated-orcid":false,"given":"Gerard","family":"de Pouvourville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5577-4017","authenticated-orcid":false,"given":"Jack","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-3681","authenticated-orcid":false,"given":"Fleur","family":"Levrat-Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-3563","authenticated-orcid":false,"given":"Anthony","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-832X","authenticated-orcid":false,"given":"Yeesha","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"673_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 10th edition 2021 [2 October 2024]. Available from: https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/"},{"issue":"1","key":"673_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2024","unstructured":"Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. In 2022. Diabetes Care. 2024;47(1):26\u201343. https:\/\/doi.org\/10.2337\/dci23-0085","journal-title":"Diabetes Care"},{"issue":"2","key":"673_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77\u201382. https:\/\/doi.org\/10.2337\/diaclin.26.2.77.","journal-title":"Clin Diabetes"},{"key":"673_CR4","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice C. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2024. Diabetes care. 2024;47(Suppl 1):S111\u2013S125. https:\/\/doi.org\/10.2337\/dc24-S006","DOI":"10.2337\/dc24-S006"},{"issue":"3","key":"673_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The diabetes & aging Study). Diabetes Care. 2019;42(3):416\u201326. https:\/\/doi.org\/10.2337\/dc17-1144.","journal-title":"Diabetes Care"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/PPA.S57567","volume":"8","author":"WM Ong","year":"2014","unstructured":"Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Prefer Adherence. 2014;8:237\u201346. https:\/\/doi.org\/10.2147\/PPA.S57567.","journal-title":"Patient Prefer Adherence"},{"key":"673_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40200-015-0172-z","volume":"14","author":"JE Ward","year":"2015","unstructured":"Ward JE, Stetson BA, Mokshagundam SP. Patient perspectives on self-monitoring of blood glucose: perceived recommendations, behaviors and barriers in a clinic sample of adults with type 2 diabetes. J Diabetes Metab Disord. 2015;14:43. https:\/\/doi.org\/10.1186\/s40200-015-0172-z.","journal-title":"J Diabetes Metab Disord"},{"issue":"Suppl 2","key":"673_CR8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1089\/dia.2015.0417","volume":"18","author":"D Rodbard","year":"2016","unstructured":"Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3\u201313. https:\/\/doi.org\/10.1089\/dia.2015.0417","journal-title":"Diabetes Technol Ther"},{"key":"673_CR9","unstructured":"FreeStyle, Libre. Abbott; [cited: 2024 Sep 10]. Available from: https:\/\/www.freestyle.abbott\/"},{"issue":"6","key":"673_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s13300-022-01253-9","volume":"13","author":"M Evans","year":"2022","unstructured":"Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022;13(6):1175\u201385. https:\/\/doi.org\/10.1007\/s13300-022-01253-9","journal-title":"Diabetes Ther"},{"issue":"1","key":"673_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13098-021-00654-3","volume":"13","author":"M Krakauer","year":"2021","unstructured":"Krakauer M, Botero JF, Lavalle-Gonzalez FJ, et al. A review of flash glucose monitoring in type 2 diabetes. Diabetol Metab Syndr. 2021;13(1):42. https:\/\/doi.org\/10.1186\/s13098-021-00654-3.","journal-title":"Diabetol Metab Syndr"},{"issue":"10057","key":"673_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31535-5.","journal-title":"Lancet"},{"issue":"1","key":"673_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55\u201373. https:\/\/doi.org\/10.1007\/s13300-016-0223-6","journal-title":"Diabetes Ther"},{"issue":"1","key":"673_CR14","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjdrc-2019-001115","volume":"8","author":"E Wada","year":"2020","unstructured":"Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8(1):e001115. https:\/\/doi.org\/10.1136\/bmjdrc-2019-001115.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"673_CR15","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2337\/dc20-0738","volume":"43","author":"H Deshmukh","year":"2020","unstructured":"Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care. 2020;43(9):2153\u201360. https:\/\/doi.org\/10.2337\/dc20-0738","journal-title":"Diabetes Care"},{"issue":"6","key":"673_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/dia.2023.0034","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci B, Levrat-Guillen F, Vicaut E, et al. Reduced acute diabetes events after FreeStyle Libre system initiation in people 65 years or older with type 2 diabetes on intensive insulin therapy in France. Diabetes Technol Ther. 2023;25(6):384\u201394. https:\/\/doi.org\/10.1089\/dia.2023.0034","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"673_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/dia.2022.0271","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci B, Roussel R, Levrat-Guillen F, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2023;25(1):20\u201330. https:\/\/doi.org\/10.1089\/dia.2022.0271","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"673_CR18","doi-asserted-by":"publisher","first-page":"bvab013","DOI":"10.1210\/jendso\/bvab013","volume":"5","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Kerr MSD, Roberts GJ, et al. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5(4):bvab013. https:\/\/doi.org\/10.1210\/jendso\/bvab013","journal-title":"J Endocr Soc"},{"key":"673_CR19","doi-asserted-by":"publisher","unstructured":"Blissett R, Blissett D, Levrat-Guillen F, et al. FreeStyle Libre flash glucose monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. BMJ Open Diabetes Res Care. 2022;10(2). https:\/\/doi.org\/10.1136\/bmjdrc-2021-002580","DOI":"10.1136\/bmjdrc-2021-002580"},{"key":"673_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"673_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"673_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51\u20139.","journal-title":"Evid Policy"},{"key":"673_CR23","doi-asserted-by":"crossref","unstructured":"Higgins JP. Cochrane handbook for systematic reviews of interventions version 5.0.1. The Cochrane Collaboration 2008. Available from: http:\/\/www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"6","key":"673_CR24","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1002\/edm2.369","volume":"5","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Lin R, Hua X, et al. A systematic review: cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes. Endocrinol Diabetes Metab. 2022;5(6):e369. https:\/\/doi.org\/10.1002\/edm2.369","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"673_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351","journal-title":"Value Health"},{"key":"673_CR26","doi-asserted-by":"publisher","first-page":"209084","DOI":"10.1016\/j.josat.2023.209084","volume":"152","author":"E Fardone","year":"2023","unstructured":"Fardone E, Montoya ID, Schackman BR, et al. Economic benefits of substance use disorder treatment: a systematic literature review of economic evaluation studies from 2003 to 2021. J Subst Use Addict Treat. 2023;152:209084. https:\/\/doi.org\/10.1016\/j.josat.2023.209084","journal-title":"J Subst Use Addict Treat"},{"issue":"11\u201312","key":"673_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s13300-022-01325-w","volume":"13","author":"R Ajjan","year":"2022","unstructured":"Ajjan R, Bilir SP, Hellmund R, et al. Cost-effectiveness analysis of flash glucose monitoring system for people with type 2 diabetes receiving intensive insulin treatment. Diabetes Ther. 2022;13(11\u201312):1933\u201345. https:\/\/doi.org\/10.1007\/s13300-022-01325-w","journal-title":"Diabetes Ther"},{"issue":"9","key":"673_CR28","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1111\/dom.15158","volume":"25","author":"H Alshannaq","year":"2023","unstructured":"Alshannaq H, Cogswell G, Pollock RF, et al. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark. Diabetes Obes Metab. 2023;25(9):2704\u201313. https:\/\/doi.org\/10.1111\/dom.15158.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"673_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13098-023-01208-5","volume":"15","author":"L Bahia","year":"2023","unstructured":"Bahia L, Mello KF, Lemos LLP, et al. Cost-effectiveness of continuous glucose monitoring with FreeStyle Libre(R) in Brazilian insulin-treated patients with types 1 and 2 diabetes mellitus. Diabetol Metab Syndr. 2023;15(1):242. https:\/\/doi.org\/10.1186\/s13098-023-01208-5","journal-title":"Diabetol Metab Syndr"},{"key":"673_CR30","unstructured":"Bidonde J, Fagerlund BC, Fronsdal KB, et al. FreeStyle Libre flash glucose self-monitoring system: a single-technology assessment. 2017."},{"issue":"2","key":"673_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.17925\/EE.2018.14.2.80","volume":"14","author":"SP Bilir","year":"2018","unstructured":"Bilir SP, Hellmund R, Wehler E, et al. The cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14(2):80\u20135. https:\/\/doi.org\/10.17925\/EE.2018.14.2.80","journal-title":"Eur Endocrinol"},{"issue":"2","key":"673_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.17925\/EE.2018.14.2.73","volume":"14","author":"SP Bilir","year":"2018","unstructured":"Bilir SP, Hellmund R, Wehler B, et al. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14(2):73\u20139. https:\/\/doi.org\/10.17925\/EE.2018.14.2.73.","journal-title":"Eur Endocrinol"},{"issue":"3","key":"673_CR33","doi-asserted-by":"publisher","first-page":"e15232","DOI":"10.1111\/dme.15232","volume":"41","author":"RA Elliott","year":"2024","unstructured":"Elliott RA, Rogers G, Evans ML, et al. Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabet Med. 2024;41(3):e15232. https:\/\/doi.org\/10.1111\/dme.15232.","journal-title":"Diabet Med"},{"issue":"1","key":"673_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/19322968221109841","volume":"18","author":"S Emamipour","year":"2024","unstructured":"Emamipour S, van Dijk PR, Bilo HJG, et al. Personalizing the use of a intermittently scanned continuous glucose monitoring device in individuals with type 1 diabetes: a cost-effectiveness perspective in the Netherlands (FLARE-NL 9). J Diabetes Sci Technol. 2024;18(1):135\u201342. https:\/\/doi.org\/10.1177\/19322968221109841","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"673_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/dia.2023.0455","volume":"26","author":"D Gardner","year":"2024","unstructured":"Gardner D, Lakkad M, Qiu Z, et al. The cost-effectiveness of an advanced hybrid closed-loop system compared to standard management of type 1 diabetes in a Singapore setting. Diabetes Technol Ther. 2024;26(5):324\u201334. https:\/\/doi.org\/10.1089\/dia.2023.0455","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"673_CR36","doi-asserted-by":"publisher","first-page":"e14831","DOI":"10.1111\/dme.14831","volume":"39","author":"JJ Isitt","year":"2022","unstructured":"Isitt JJ, Roze S, Tilden D, et al. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia. Diabet Med. 2022;39(7):e14831. https:\/\/doi.org\/10.1111\/dme.14831.","journal-title":"Diabet Med"},{"issue":"12","key":"673_CR37","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s13300-021-01172-1","volume":"12","author":"J Jendle","year":"2021","unstructured":"Jendle J, Eeg-Olofsson K, Svensson AM, et al. Cost-effectiveness of the FreeStyle Libre((R)) system versus blood glucose self-monitoring in individuals with type 2 diabetes on insulin treatment in Sweden. Diabetes Ther. 2021;12(12):3137\u201352. https:\/\/doi.org\/10.1007\/s13300-021-01172-1","journal-title":"Diabetes Ther"},{"issue":"11","key":"673_CR38","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s13300-021-01157-0","volume":"12","author":"J Jendle","year":"2021","unstructured":"Jendle J, Buompensiere MI, Holm AL, et al. The cost-effectiveness of an advanced hybrid closed-loop system in people with type 1 diabetes: a health economic analysis in Sweden. Diabetes Ther. 2021;12(11):2977\u201391. https:\/\/doi.org\/10.1007\/s13300-021-01157-0","journal-title":"Diabetes Ther"},{"issue":"12","key":"673_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1089\/dia.2023.0297","volume":"25","author":"J Jendle","year":"2023","unstructured":"Jendle J, Buompensiere MI, Ozdemir Saltik AZ, et al. A European cost-utility analysis of the MiniMed 780G advanced hybrid closed-loop system versus intermittently scanned continuous glucose monitoring with multiple daily insulin injections in people living with type 1 diabetes. Diabetes Technol Ther. 2023;25(12):864\u201376. https:\/\/doi.org\/10.1089\/dia.2023.0297","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"673_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/dia.2021.0443","volume":"24","author":"V Lambadiari","year":"2022","unstructured":"Lambadiari V, Ozdemir Saltik AZ, de Portu S, et al. Cost-effectiveness analysis of an advanced hybrid closed-loop insulin delivery system in people with type 1 diabetes in Greece. Diabetes Technol Ther. 2022;24(5):316\u201323. https:\/\/doi.org\/10.1089\/dia.2021.0443","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"673_CR41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2337\/dc21-2341","volume":"45","author":"MA Rotondi","year":"2022","unstructured":"Rotondi MA, Wong O, Riddell M, et al. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modeling study. Diabetes Care. 2022;45(9):2012\u20139. https:\/\/doi.org\/10.2337\/dc21-2341","journal-title":"Diabetes Care"},{"issue":"4","key":"673_CR42","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s12325-022-02058-9","volume":"39","author":"EH Serne","year":"2022","unstructured":"Serne EH, Roze S, Buompensiere MI, et al. Cost-effectiveness of hybrid closed loop insulin pumps versus multiple daily injections plus intermittently scanned glucose monitoring in people with type 1 diabetes in the Netherlands. Adv Ther. 2022;39(4):1844\u201356. https:\/\/doi.org\/10.1007\/s12325-022-02058-9","journal-title":"Adv Ther"},{"issue":"4","key":"673_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s00125-023-06084-2","volume":"67","author":"MM Visser","year":"2024","unstructured":"Visser MM, Van Muylder A, Charleer S, et al. Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium. Diabetologia. 2024;67(4):650\u201362. https:\/\/doi.org\/10.1007\/s00125-023-06084-2","journal-title":"Diabetologia"},{"issue":"12","key":"673_CR44","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s13300-021-01166-z","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao X, Ming J, Qu S, et al. Cost-effectiveness of flash glucose monitoring for the management of patients with type 1 and patients with type 2 diabetes in China. Diabetes Ther. 2021;12(12):3079\u201392. https:\/\/doi.org\/10.1007\/s13300-021-01166-z","journal-title":"Diabetes Ther"},{"issue":"2","key":"673_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2337\/dc22-1219","volume":"46","author":"RA Ajjan","year":"2023","unstructured":"Ajjan RA, Heller SR, Everett CC, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes Care. 2023;46(2):441\u20139. https:\/\/doi.org\/10.2337\/dc22-1219","journal-title":"Diabetes Care"},{"issue":"3","key":"673_CR46","doi-asserted-by":"publisher","first-page":"e14747","DOI":"10.1111\/dme.14747","volume":"39","author":"X Hua","year":"2022","unstructured":"Hua X, Catchpool M, Clarke P, et al. Cost-effectiveness of professional-mode flash glucose monitoring in general practice among adults with type 2 diabetes: evidence from the GP-OSMOTIC trial. Diabet Med. 2022;39(3):e14747. https:\/\/doi.org\/10.1111\/dme.14747.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"673_CR47","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1185\/030079904x1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5\u201326. https:\/\/doi.org\/10.1185\/030079904x1980.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"673_CR48","doi-asserted-by":"publisher","first-page":"147916412110674","DOI":"10.1177\/14791641211067418","volume":"20","author":"K Eeg-Olofsson","year":"2023","unstructured":"Eeg-Olofsson K, Svensson AM, Franz\u00e9n S, et al. Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish national diabetes register. Diabetes Vasc Dis Res. 2023;20(1):14791641211067418. https:\/\/doi.org\/10.1177\/14791641211067418","journal-title":"Diabetes Vasc Dis Res"},{"issue":"2","key":"673_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/s2213-8587(22)00352-7","volume":"11","author":"MM Visser","year":"2023","unstructured":"Visser MM, Charleer S, Fieuws S, et al. Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial. Lancet Diabetes Endocrinol. 2023;11(2):96\u2013108. https:\/\/doi.org\/10.1016\/s2213-8587(22)00352-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"673_CR50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.pcd.2024.04.003","volume":"18","author":"A Gutierrez-Pastor","year":"2024","unstructured":"Gutierrez-Pastor A, Quesada JA, Soler-Martinez MM, et al. Effect of switch from flash glucose monitoring to flash glucose monitoring with real-time alarms on hypoglycaemia in people with type 1 diabetes mellitus. Prim Care Diabetes. 2024;18(3):333\u20139. https:\/\/doi.org\/10.1016\/j.pcd.2024.04.003.","journal-title":"Prim Care Diabetes"},{"issue":"11","key":"673_CR51","doi-asserted-by":"publisher","first-page":"e15130","DOI":"10.1111\/dme.15130","volume":"40","author":"RH Stimson","year":"2023","unstructured":"Stimson RH, Dover AR, Strachan MWJ, et al. Changes in continuous glucose monitoring metrics and predictors of improvement 12 months after conversion from FreeStyle Libre to FreeStyle Libre 2. Diabet Med. 2023;40(11):e15130. https:\/\/doi.org\/10.1111\/dme.15130","journal-title":"Diabet Med"},{"key":"673_CR52","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.ajmo.2022.100008","volume":"9","author":"E Miller","year":"2023","unstructured":"Miller E, Roberts GJ, Joseph JM, et al. Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes. Am J Med Open. 2023;9:100008. https:\/\/doi.org\/10.1016\/j.ajmo.2022.100008.","journal-title":"Am J Med Open"},{"issue":"6","key":"673_CR53","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","volume":"17","author":"P McEwan","year":"2014","unstructured":"McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714\u201324. https:\/\/doi.org\/10.1016\/j.jval.2014.07.007.","journal-title":"Value Health"},{"key":"673_CR54","doi-asserted-by":"publisher","first-page":"111786","DOI":"10.1016\/j.diabres.2024.111786","volume":"214","author":"A Ortiz-Z\u00fa\u00f1iga","year":"2024","unstructured":"Ortiz-Z\u00fa\u00f1iga A, Amig\u00f3 J, S\u00e1nchez M, et al. Impact in real-world of intermittent-scanned continuous glucose monitoring with alarms on hypoglycemia and its recognition in type 1 diabetes. Diabetes Res Clin Pract. 2024;214:111786. https:\/\/doi.org\/10.1016\/j.diabres.2024.111786.","journal-title":"Diabetes Res Clin Pract"},{"key":"673_CR55","doi-asserted-by":"publisher","first-page":"117955141774695","DOI":"10.1177\/1179551417746957","volume":"10","author":"AA Al Hayek","year":"2017","unstructured":"Al Hayek AA, Robert AA, Al Dawish MA. Evaluation of FreeStyle Libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10:1179551417746957. https:\/\/doi.org\/10.1177\/1179551417746957","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"5","key":"673_CR56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/dia.2019.0417","volume":"22","author":"A Pease","year":"2020","unstructured":"Pease A, Lo C, Earnest A, et al. The efficacy of technology in type 1 diabetes: a systematic review, network meta-analysis, and narrative synthesis. Diabetes Technol Ther. 2020;22(5):411\u201321. https:\/\/doi.org\/10.1089\/dia.2019.0417","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"673_CR57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1089\/dia.2024.0102","volume":"26","author":"J Mustonen","year":"2024","unstructured":"Mustonen J, Rautiainen P, Lamidi ML, et al. Long-term health economic evaluation of intermittently scanned glucose monitoring compared with self-monitoring blood glucose in a real-world setting in Finnish adult individuals with type 1 diabetes. Diabetes Technol Ther. 2024;26(12):918\u201324. https:\/\/doi.org\/10.1089\/dia.2024.0102","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"673_CR58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13300-024-01677-5","volume":"16","author":"S Harris","year":"2025","unstructured":"Harris S, Cimino S, Nguyen Y, et al. Cost-effectiveness of FreeStyle Libre for glucose self-management among people with diabetes mellitus: a Canadian private payer perspective. Diabetes Ther. 2025;16(2):169\u201386. https:\/\/doi.org\/10.1007\/s13300-024-01677-5","journal-title":"Diabetes Ther"},{"issue":"9","key":"673_CR59","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1111\/dom.15703","volume":"26","author":"S Del Prato","year":"2024","unstructured":"Del Prato S, Giorgino F, Szafranski K, et al. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-an Italian healthcare system perspective. Diabetes Obes Metab. 2024;26(9):3633\u201341. https:\/\/doi.org\/10.1111\/dom.15703","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"673_CR60","doi-asserted-by":"publisher","first-page":"917","DOI":"10.18553\/jmcp.2024.24025","volume":"30","author":"J Frank","year":"2024","unstructured":"Frank J, Son D, Szafranski K, et al. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: a microsimulation model and cost-effectiveness analysis from a US perspective with relevance to medicaid. J Managed Care Specialty Pharm. 2024;30(9):917\u201328. https:\/\/doi.org\/10.18553\/jmcp.2024.24025","journal-title":"J Managed Care Specialty Pharm"},{"issue":"2","key":"673_CR61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.18553\/jmcp.2025.24253","volume":"31","author":"EE Wright","year":"2025","unstructured":"Wright EE, Miller E, Bindal A, et al. Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - an economic evaluation. J Managed Care Specialty Pharm. 2025;31(2):127\u201336. https:\/\/doi.org\/10.18553\/jmcp.2025.24253","journal-title":"J Managed Care Specialty Pharm"},{"key":"673_CR62","unstructured":"Norwegian Ministry of Health and Care Services. Principles for priority setting in health care 2017 [cited: 2024 Nov 12]. Available from: https:\/\/www.regjeringen.no\/contentassets\/439a420e01914a18b21f351143ccc6af\/en-gb\/pdfs\/stm201520160034000engpdfs.pdf"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00673-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00673-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00673-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:12:41Z","timestamp":1781615561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00673-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00673-1","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GdP. has received honoraria from Abbott as a scientific adviser for ongoing real-world studies of FSL. JT, FL-G, and YP are employees of Abbott. AZ is an employee of EVERSANA, which has received project funding from Abbott.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}